1stOncology™: Cancer Intelligence Service – Page 15100 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases

On January 29, 2018 Innovation Pharmaceuticals, (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company,reported a business development update (Press release, Innovation Pharmaceuticals, JAN 29, 2018, View Source [SID1234523613]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

· The Confidential Disclosure Agreement (CDA) count toward partnering with global and specialty pharmaceutical companies interested in the Company’s first-in-class drug candidates is nearing 20, with additional Agreements in review. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties;

· A leading international drug manufacturer has been engaged with to bulk produce commercial-quality Brilacidin, aimed at lowering patient drug cost and anticipating future drug needs in preparation for expedient market introduction. This critical step also proactively facilitates future patient and insurance reimbursement adoption through favorable cost savings;

· After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years.

Brilacidin—Dermatology Formulation Development

Brilacidin has successfully completed Phase 2 trials in Oral Mucositis (OM), Inflammatory Bowel Disease (IBD) and Acute Bacterial Skin and Structure Infection (ABSSSI). A drug with broad platform potential (pdf), Brilacidin’s innate properties and modes of action, as well as additional pre-clinical work, support the drug’s potential for topical application in dermatology, including: Atopic Dermatitis, Acne, and Hidradenitis Suppurativa. All are areas of large unmet need and comprise highly lucrative markets.

To further these efforts, the Company is in negotiations with a leading drug formulator to develop topical formulation(s) of Brilacidin for these three dermatology indications, starting in 1H2018. The goal of the negotiations is to reach terms on a strategic partnership for addressing these markets. The formulator brings an impressive track record of developing products that have earned billions of dollars for global pharmaceutical companies.

For a discussion on Brilacidin’s potential as a topical agent in dermatology, please read more at the following link:

· "Brilacidin’s Potential Application in Dermatology"

For more on Brilacidin, learn more here:

· View Source

Agilent Announces Scientific Collaboration with the University of Southern California

On January 29, 2018 Agilent Technologies Inc. (NYSE: A) reported that it has formed a strategic scientific collaboration with the University of Southern California (USC) Michelson Center for Convergent Bioscience to create an Agilent Center of Excellence (COE) in Biomolecular Characterization (Press release, Agilent, JAN 29, 2018, http://www.agilent.com/about/newsroom/presrel/2018/29jan-ca17038.html [SID1234523609]).

The center will be housed in Michelson Hall, which opened at the university in October 2017 and is a state-of-the-art research facility aimed at establishing a convergence of researchers across science and engineering to work together on multidisciplinary approaches for the development of improved health care through new drugs, diagnostics, and medical devices. The Agilent COE will be a resource for undergraduate and graduate students as well as customers in the area, providing access to new Agilent instrumentation and broad exposure to researchers who are leaders in their respective fields.

"Agilent’s collaboration with the Michelson Center is an excellent example of how academia and industry can work together, sharing knowledge and expertise to shorten the timeline between scientific discoveries and real-world applications," said Darlene Solomon, senior vice president and chief technology officer for Agilent. "Convergent bioscience research requires successful collaboration across multiple disciplines — a holistic approach that is central to Agilent’s view of the future."

Key to the Agilent COE will be collaboration with renowned USC Michelson Center for Convergent Bioscience principal investigator Dr. Valery Fokin. Research at the Fokin lab at USC focuses on chemical reactivity and biological interactions at the molecular level. The lab will contribute to multiple collaborative drug discovery projects ranging from chemical synthesis of screening and focused libraries and biological assay implementation to the development of targeted drug delivery systems, diagnostics, and vaccines.

"As convergent bioscience becomes a major contributor to scientific knowledge and ultimately improved human health, academic and industry collaboration will play a key role," said Stephen Bradforth, divisional dean for natural sciences and mathematics at the USC Dornsife College of Letters, Arts and Sciences. "I’m pleased that Agilent has the vision to support our efforts in this important emerging research field."

Additional notable contributors to this collaboration include Dr. Richard Roberts, chair of the Mork Family Department of Chemical Engineering and Materials Science and professor of chemistry, chemical engineering, and biomedical engineering, and Dr. Steve Kay, who is Provost Professor of Neurology, Biomedical Engineering and Biological Sciences. Dr. Roberts, who is co-director of the Agilent COE with Dr. Fokin, is a renowned expert in the chemical biology of protein synthesis whose breakthrough methods allow researchers to screen 10 trillion independent peptide or protein sequences to understand their functions. Dr. Kay’s research into high-throughput genomics and chemical biology has been integral to the understanding of circadian rhythms, and he is recognized as one of the world’s top experts in this area. Other contributors are Dr. Raymond C. Stevens, Provost Professor of Biological Sciences and Chemistry, and Dr. Peter Kuhn, Dean’s Professor of Biological Sciences. Dr. Stevens and Dr. Kuhn are among the world’s most influential biomedical scientists; their research on structural biology and cancer metastasis have led to important advances in medical treatments and pharmaceutical drugs.

Presentation Material (Third Quarter Financial Results for FY2017)

On January 29, 2018 Sumitomo Dainippon Pharma presented Presentation Material (Third Quarter Financial Results for FY2017) (Press release, Dainippon Sumitomo Pharma, JAN 29, 2018, View Source [SID1234523623]).

DiaMedica to Present at the 14th Annual Noble Investor Conference

On January 29, 2018 DiaMedica Therapeutics Inc. (TSXV:DMA) (OTCQB:DMCAF), reported that Mr. Rick Pauls, its President and CEO, will present at Noble Capital Markets’ Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Tuesday, January 30th at 01:30 pm EST – Studio 1 (Press release, DiaMedica, JAN 29, 2018, View Source [SID1234523653]).

Innate Pharma and MedImmune enter clinical trial collaboration

On January 30, 2018 Innate Pharma SA (the "Company" – Euronext Paris: FR0010331421 – IPH) reported that it has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (Press release, Innate Pharma, JAN 29, 2018, View Source [SID1234523634]). The Phase I/II study (STELLAR-001) will evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with Innate’s investigational anti-C5aR monoclonal antibody, IPH5401, as a treatment for patients with selected solid tumors.

"Our collaboration with MedImmune provides further evidence of Innate’s commitment to exploring the full combination potential of IPH5401 as we progress our immuno-oncology portfolio," said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. "We believe IPH5401 could become an important partner in PD-1/PD-L1 combination strategies."

The Phase I part of the trial is expected to establish a recommended dose regimen of IPH5401 in combination with durvalumab in selected solid tumors, and the Phase II part will assess the safety and efficacy of the combination in these patients. The study will be conducted by Innate and the costs will be equally shared by both parties. The agreement between Innate Pharma and MedImmune is non-exclusive.

Both durvalumab and IPH5401 are cancer immunotherapies, a potent class of treatments that use the body’s own immune system to help fight cancer. Durvalumab blocks PD-L1 interactions with PD-1 and CD80, countering the tumor’s immune-evading tactics and inducing an immune response. Preclinical findings suggest that C5aR blockade increases immune-mediated tumor killing and efficacy of checkpoint inhibitors. Complement cascade factor 5a (C5a), secreted by tumor cells, attracts and stimulates C5aR-overexpressing myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment. Part of the innate immune system, these types of cells promote tumor growth by secreting inflammatory mediators, immunosuppressive cytokines and angiogenic factors. They potently suppress T and NK cells and hamper the activities of PD-1/PD-L1 checkpoint blockers.

Innate Pharma and AstraZeneca have an existing co-development and commercialization agreement for monalizumab, a first-in-class humanized IgG4 targeting NKG2A receptors expressed on tumor infiltrating cytotoxic NK and CD8 T lymphocytes.